Sertraline may increase the hypoglycemic activities of Canagliflozin. The metabolism of Sertraline can be decreased when combined with Trimethoprim. Sertraline may increase the QTc-prolonging activities of Telavancin. The serum concentration of Sertraline can be decreased when it is combined with Enzalutamide. The metabolism of Loratadine can be decreased when combined with Sertraline. Sufentanil may increase the serotonergic activities of Sertraline. The risk or severity of adverse effects can be increased when Sertraline is combined with Rasagiline. The metabolism of Methoxyflurane can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Sertraline is combined with Reserpine. The metabolism of Oxiconazole can be decreased when combined with Sertraline. The metabolism of Axitinib can be decreased when combined with Sertraline. The metabolism of Tolterodine can be decreased when combined with Sertraline. The serum concentration of Sertraline can be decreased when it is combined with Cyproterone acetate. The metabolism of Chlorphenamine can be decreased when combined with Sertraline. The metabolism of Carbinoxamine can be decreased when combined with Sertraline. Phenoxypropazine may increase the serotonergic activities of Sertraline. The serum concentration of Sertraline can be increased when it is combined with Luliconazole. Sertraline may increase the hypoglycemic activities of Mecasermin. Pentazocine may increase the serotonergic activities of Sertraline. Sertraline may increase the hyponatremic activities of Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Triprolidine is combined with Sertraline. The serum concentration of Landiolol can be increased when it is combined with Sertraline. The serum concentration of Sertraline can be decreased when it is combined with Peginterferon alfa-2b. The metabolism of Glucosamine can be decreased when combined with Sertraline. Sertraline may increase the QTc-prolonging activities of Gemifloxacin. The metabolism of Sertindole can be decreased when combined with Sertraline. L-Tryptophan may increase the serotonergic activities of Sertraline. The metabolism of Enasidenib can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Ziconotide is combined with Sertraline. The metabolism of Cephalexin can be decreased when combined with Sertraline. The serum concentration of Clozapine can be increased when it is combined with Sertraline. Sertraline may increase the QTc-prolonging activities of Propafenone. The risk or severity of adverse effects can be increased when Sertraline is combined with Propericiazine. The metabolism of Halothane can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Sertraline is combined with Ritanserin. The metabolism of Clevidipine can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertraline. The metabolism of Propranolol can be decreased when combined with Sertraline. The metabolism of Methylphenidate can be decreased when combined with Sertraline. The serum concentration of Cerivastatin can be increased when it is combined with Sertraline. The serum concentration of Pitavastatin can be increased when it is combined with Sertraline. The metabolism of Tamsulosin can be decreased when combined with Sertraline. The metabolism of Tofacitinib can be decreased when combined with Sertraline. The metabolism of Methadone can be decreased when combined with Sertraline. Normethadone may increase the serotonergic activities of Sertraline. Sertraline may increase the QTc-prolonging activities of Chlorpromazine. Sertraline may increase the QTc-prolonging activities of Zuclopenthixol. The metabolism of Ketamine can be decreased when combined with Sertraline. The metabolism of 4-Methoxyamphetamine can be decreased when combined with Sertraline. The metabolism of Zidovudine can be decreased when combined with Sertraline. The metabolism of Halofantrine can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Ethotoin is combined with Sertraline. Sertraline may increase the hyponatremic activities of Hydroflumethiazide. The metabolism of Acetaminophen can be decreased when combined with Sertraline. The metabolism of Sertraline can be decreased when combined with Verapamil. The metabolism of Bromazepam can be decreased when combined with Sertraline. The serum concentration of Bupranolol can be increased when it is combined with Sertraline. The metabolism of Isoflurane can be decreased when combined with Sertraline. The metabolism of Sertraline can be decreased when combined with Indinavir. Sertraline may increase the QTc-prolonging activities of Bedaquiline. Sertraline may increase the QTc-prolonging activities of Ciprofloxacin. The serum concentration of Sertraline can be decreased when it is combined with Darunavir. The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sertraline. The serum concentration of Nadolol can be increased when it is combined with Sertraline. Sertraline may increase the hyponatremic activities of Bendroflumethiazide. Sertraline may increase the hypoglycemic activities of Rosiglitazone. The metabolism of Sertraline can be decreased when combined with Fluconazole. The serum concentration of Sertraline can be increased when it is combined with Netupitant. The risk or severity of adverse effects can be increased when Scopolamine is combined with Sertraline. Sertraline may increase the antiplatelet activities of Etoricoxib. The serum concentration of Pravastatin can be increased when it is combined with Sertraline. The risk or severity of adverse effects can be increased when Etidocaine is combined with Sertraline. The metabolism of Mirabegron can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Fludiazepam is combined with Sertraline. The serum concentration of Ubidecarenone can be increased when it is combined with Sertraline. The metabolism of Sertraline can be decreased when combined with Telithromycin. The metabolism of Ambrisentan can be decreased when combined with Sertraline. The metabolism of Mianserin can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Olopatadine is combined with Sertraline. The risk or severity of adverse effects can be increased when Sertraline is combined with Amineptine. The serum concentration of Thioridazine can be increased when it is combined with Sertraline. The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Sertraline. The serum concentration of Brentuximab vedotin can be increased when it is combined with Sertraline. The risk or severity of adverse effects can be increased when Ketazolam is combined with Sertraline. Sertraline may increase the anticoagulant activities of Ethyl biscoumacetate. The metabolism of Dapsone can be decreased when combined with Sertraline. The metabolism of Acenocoumarol can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Sepranolone is combined with Sertraline. Alphaprodine may increase the serotonergic activities of Sertraline. The serum concentration of Edoxaban can be increased when it is combined with Sertraline. The metabolism of Sertraline can be decreased when combined with Topiroxostat. The metabolism of Brivaracetam can be decreased when combined with Sertraline. The metabolism of Tretinoin can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Sertraline is combined with Bromocriptine. The metabolism of Thalidomide can be decreased when combined with Sertraline. The metabolism of Sertraline can be decreased when combined with Sildenafil. Sertraline may increase the QTc-prolonging activities of Anagrelide. The metabolism of Sertraline can be decreased when combined with Ticlopidine. Sertraline may increase the hypoglycemic activities of Tolazamide. Nialamide may increase the serotonergic activities of Sertraline. Sertraline may increase the hypoglycemic activities of Pioglitazone. The risk or severity of adverse effects can be increased when Flurazepam is combined with Sertraline. The metabolism of Sertraline can be decreased when combined with Caffeine. The metabolism of Pindolol can be decreased when combined with Sertraline. The serum concentration of Bucindolol can be increased when it is combined with Sertraline. The metabolism of Irinotecan can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Alfaxalone is combined with Sertraline. Sertraline may increase the QTc-prolonging activities of Quinine. Sertraline may increase the hyponatremic activities of Trichlormethiazide. The metabolism of Yohimbine can be decreased when combined with Sertraline. Sertraline may increase the QTc-prolonging activities of Domperidone. The metabolism of Sertraline can be decreased when combined with Chloramphenicol. The therapeutic efficacy of Codeine can be decreased when used in combination with Sertraline. Sertraline may increase the hypoglycemic activities of Insulin Glulisine. Dextromoramide may increase the serotonergic activities of Sertraline. The risk or severity of adverse effects can be increased when Perampanel is combined with Sertraline. The metabolism of Sertraline can be decreased when combined with Idelalisib. Sertraline may increase the QTc-prolonging activities of Goserelin. The metabolism of Bufuralol can be decreased when combined with Sertraline. The metabolism of Sertraline can be decreased when combined with Sulfisoxazole. The risk or severity of adverse effects can be increased when Adipiplon is combined with Sertraline. The metabolism of Flutamide can be decreased when combined with Sertraline. The metabolism of Sertraline can be decreased when combined with Theophylline. The metabolism of Meprobamate can be decreased when combined with Sertraline. The metabolism of Flunitrazepam can be decreased when combined with Sertraline. The metabolism of Troglitazone can be decreased when combined with Sertraline. The risk or severity of adverse effects can be increased when Prazepam is combined with Sertraline. The metabolism of Rosuvastatin can be decreased when combined with Sertraline. The serum concentration of Ibrutinib can be increased when it is combined with Sertraline. The risk or severity of adverse effects can be increased when Sertraline is combined with Tetrahydropalmatine.